United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $562.82, for a total transaction of $4,671,406.00. Following the sale, the executive vice president owned 45,172 shares in the company, valued at $25,423,705.04. This represents a 15.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
United Therapeutics Stock Performance
NASDAQ UTHR opened at $568.43 on Friday. The firm has a market cap of $24.13 billion, a PE ratio of 20.98, a P/E/G ratio of 1.84 and a beta of 0.60. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The firm’s fifty day moving average is $563.25 and its two-hundred day moving average is $511.57.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $6.63 earnings per share. Research analysts predict that United Therapeutics Corporation will post 27.07 earnings per share for the current year.
Analyst Ratings Changes
Read Our Latest Research Report on UTHR
Institutional Trading of United Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Arjuna Capital boosted its holdings in shares of United Therapeutics by 2.8% in the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after acquiring an additional 18 shares in the last quarter. Clearstead Advisors LLC boosted its holdings in shares of United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock valued at $117,000 after acquiring an additional 23 shares in the last quarter. Sage Rhino Capital LLC boosted its holdings in shares of United Therapeutics by 5.1% in the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock valued at $281,000 after acquiring an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC boosted its holdings in shares of United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 24 shares in the last quarter. Finally, Meeder Advisory Services Inc. boosted its holdings in shares of United Therapeutics by 4.1% in the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock valued at $392,000 after acquiring an additional 26 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.
United Therapeutics Company Profile
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Read More
- Five stocks we like better than United Therapeutics
- Workday Validates AI Flywheel: Stock Price Recovery Begins
- HubSpot at 2019 Levels Is an Opportunity—Not a Warning
- Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?
- Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
